An international multicenter, open-label phase I study enrolled 54 patients with advanced ALK-positive or ROS1-positive NSCLC to receive lorlatinib at varying doses, including 24 with baseline measurable BM [46]. This evidence concerns the gene ALK and non-small cell lung carcinoma.